Skip to content

Safety and Efficacy of Multivitamin-Enriched Compound Protein Nutrient (Type ?) Special Diet for Long-term Nutritional Support in Malignant Tumor Patients

Safety and Efficacy of Multivitamin-Enriched Compound Protein Nutrient (Type ?) Special Diet for Long-term Nutritional Support in Malignant Tumor Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116045
Enrollment
Unknown
Registered
2026-01-05
Start date
2026-01-06
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Tumor

Interventions

Experimental Group:Standard Antitumor Therapy + Type ? Multivitamin-Fortified Compound Protein Nutrient (Special Medical Food, SMF) (3 sachets per day, taken in divided doses
mixed with warm water (<45?) 15-30 minutes before meals for consumption, for 12 consecutive weeks)
Control Group:Standard Antitumor Therapy + Basic Diet (with dietary guidance provided in accordance with the Chinese Guidelines for Nutritional Therapy of Tumors)

Sponsors

San Liu San Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18 to 80 years old, gender not limited; 2. Patients with malignant tumors confirmed by histopathology or cytology; 3. The nutritional risk screening (NRS-2002) score is greater than or equal to 3 points, or there is definite malnutrition (serum albumin =6 months; 5. Be able to receive nutritional support through oral intake or enteral nutrition routes such as nasogastric tubes and nasojejunal tubes, and plan for long-term (=12 weeks) nutritional support; 6. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. People who are allergic to the special diet ingredients of multi-dimensional fortified complex protein nutrient (Type I); 2. Those with severe gastrointestinal dysfunction who cannot tolerate enteral nutrition; 3. Those with severe complications such as severe infection, heart failure, and respiratory failure; 4. Patients with mental disorders or cognitive dysfunction are unable to cooperate with the research; 5. Pregnant or lactating women; 6. Participated in other clinical trials within one month prior to enrollment; 7. Other circumstances that the researcher deems unsuitable for inclusion in this study.

Design outcomes

Primary

MeasureTime frame
Changes in weight-related indicators;

Secondary

MeasureTime frame
Serum albumin levels;Performance status scores;Quality of life (QoL) scores;Tolerance to antitumor therapy;Incidence of adverse events (AEs);

Countries

China

Contacts

Public ContactHongyu Xu

San Liu San Hospital

930024691@qq.com+86 135 5875 8386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026